Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.

International journal of cancer - 15 Jul 2009

Lounnas Nadia, Frelin Catherine, Gonthier Nadège, Colosetti Pascal, Sirvent Anne, Cassuto Jil-Patrice, Berthier Fréderic, Sirvent Nicolas, Rousselot Philippe, Dreano Michel, Peyron Jean-François, Imbert Véronique

Abstract excerpt

The Bcr-Abl inhibitor imatinib is the current first-line therapy for all newly diagnosed chronic myeloid leukemia (CML). Nevertheless, resistance to imatinib emerges as CML progresses to an acute deadly phase implying that physiopathologically relevant cellular targets should be validated to develop alternative therapeutic strategies. The NF-kappaB transcription factor that exerts pro-survival actions is found...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fluorescent Antibody Technique

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to NF-kappa B

Share to Piperazines

Share to Pyrimidines

Source

Identifiers

PMID: 19378338
DOI: 10.1002/ijc.24294

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.PMID 19378338Read ↗

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-AblSemantic proximity Read ↗

NF-κB: A Druggable Target in Acute Myeloid LeukemiaSemantic proximity Read ↗

IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1Semantic proximity Read ↗

Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.Semantic proximity Read ↗

Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell TranscriptomicsSemantic proximity Read ↗

NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells.Semantic proximity Read ↗

Nuclear factor B as a target for new drug development in myeloid malignanciesSemantic proximity Read ↗

Constitutive NF-κB activation in AML: Causes and treatment strategies.Semantic proximity Read ↗

NF-κB and IKK as therapeutic targets in cancerSemantic proximity Read ↗

PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.Semantic proximity Read ↗

Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of ViewSemantic proximity Read ↗

NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.